Rhumbline Advisers Has $214,000 Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Rhumbline Advisers boosted its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 37.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,357 shares of the company’s stock after buying an additional 3,627 shares during the quarter. Rhumbline Advisers’ holdings in Lexeo Therapeutics were worth $214,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in Lexeo Therapeutics during the first quarter valued at about $75,000. American International Group Inc. acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth about $79,000. Bank of New York Mellon Corp boosted its stake in Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after purchasing an additional 3,483 shares during the period. Cornell University acquired a new stake in Lexeo Therapeutics in the 1st quarter valued at approximately $1,980,000. Finally, Vanguard Group Inc. increased its position in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after buying an additional 65,573 shares during the period. Institutional investors own 60.67% of the company’s stock.

Insider Buying and Selling at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $11.53, for a total value of $57,650.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $1,391,613.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 36,969 shares of company stock valued at $555,889 in the last quarter. 4.50% of the stock is currently owned by insiders.

Lexeo Therapeutics Stock Up 2.2 %

Shares of Lexeo Therapeutics stock opened at $9.11 on Friday. The firm has a market cap of $300.13 million and a PE ratio of -0.41. The business’s 50 day simple moving average is $11.24 and its 200 day simple moving average is $13.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. Lexeo Therapeutics, Inc. has a 52-week low of $8.64 and a 52-week high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.64). On average, analysts predict that Lexeo Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on LXEO. Chardan Capital reissued a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a report on Wednesday, August 14th. Baird R W upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research note on Thursday, June 13th. Robert W. Baird assumed coverage on Lexeo Therapeutics in a research note on Thursday, June 13th. They set an “outperform” rating and a $28.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Finally, HC Wainwright decreased their price objective on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $22.14.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.